Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Optimi Health ( (TSE:OPTI) ) has shared an announcement.
Optimi Health has completed the export of its GMP-manufactured natural 5 mg psilocybin capsules to Australia for use in patients with treatment-resistant depression under the country’s Authorised Prescriber Scheme. This marks the company’s second psychedelic drug product in the Australian market, joining its 40 mg and 60 mg MDMA capsules for PTSD, and underscores its fully integrated production model and growing role in regulated psychedelic-assisted therapy.
The new psilocybin capsules will be available through authorised clinics, including programs that may be reimbursed by Australia’s Department of Veterans’ Affairs, potentially broadening patient access and supporting real-world data collection through a national patient registry with the Australian National University. By leveraging its Drug Establishment Licence to export pharmaceutical-grade products internationally, Optimi strengthens its position in the emerging medical psychedelics sector and deepens its commercial foothold in Australia’s regulated therapeutic framework.
The most recent analyst rating on (TSE:OPTI) stock is a Hold with a C$0.36 price target. To see the full list of analyst forecasts on Optimi Health stock, see the TSE:OPTI Stock Forecast page.
Spark’s Take on TSE:OPTI Stock
According to Spark, TipRanks’ AI Analyst, TSE:OPTI is a Neutral.
The score is held down primarily by weak financial performance (small/declining revenue, large losses, persistent cash burn, and higher leverage). Technicals are comparatively supportive with price trading above major moving averages and positive momentum, but valuation is constrained by ongoing losses and the lack of dividend yield data.
To see Spark’s full report on TSE:OPTI stock, click here.
More about Optimi Health
Optimi Health Corp. is a Health Canada-licensed, GMP-compliant pharmaceutical manufacturer specializing in prescribed psychedelic treatments for mental health, including validated MDMA and botanical psilocybin products. Operating from two 10,000-square-foot facilities in British Columbia, the company supplies active pharmaceutical ingredients and finished dosage forms to regulated channels, with products available for prescription use in Australia and accessible in Canada via the Special Access Program.
Average Trading Volume: 92,148
Technical Sentiment Signal: Buy
Current Market Cap: C$36.65M
For an in-depth examination of OPTI stock, go to TipRanks’ Overview page.